Description
KC7F2 is a potent hypoxia inducible factor-1 (HIF-1) pathway inhibitor with an IC50 of 20 μM in LN229-HRE-AP cells, and with potential as a cancer therapy agent.
Product information
CAS Number: 927822-86-4
Molecular Weight: 570.38
Formula: C16H16Cl4N2O4S4
Chemical Name: 2,5-dichloro-N-(2-{[2-(2,5-dichlorobenzenesulfonamido)ethyl]disulfanyl}ethyl)benzene-1-sulfonamide
Smiles: O=S(=O)(NCCSSCCNS(=O)(=O)C1C=C(Cl)C=CC=1Cl)C1C=C(Cl)C=CC=1Cl
InChiKey: REQLACDIZMLXIC-UHFFFAOYSA-N
InChi: InChI=1S/C16H16Cl4N2O4S4/c17-11-1-3-13(19)15(9-11)29(23,24)21-5-7-27-28-8-6-22-30(25,26)16-10-12(18)2-4-14(16)20/h1-4,9-10,21-22H,5-8H2
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: DMSO : ≥ 32 mg/mL (56.10 mM).
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vitro:
KC7F2 (15–25 μM; 0-72 hours) exhibits a clear dose-response cytotoxicity with an IC50 value of approximately 15–25 μM depending on the cell lines, and this effect is more severe under hypoxic conditions. KC7F2 (0-80 μM; 6 hours) specifically reduces the protein levels of HIF-1α in a dose-dependent manner under hypoxic conditions; strongly decrease in HIF-1α levels at concentrations above 20 μM. KC7F2 does not affect the rate of HIF-1α protein degradation. KC7F2 inhibits HIF-1α protein synthesis but not its mRNA transcription. KC7F2 represses the phosphorylation of eukaryotic initiation factor 4E binding protein 1 (4EBP1).
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.